Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Hiroyoshi Kakuyama"'
1
Akademický článek
Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers
Autor: Naoto Noda, Takeshi Takagaki, Yasuhide Yodo, Yuzo Horibuchi, Shuichi Iino, Shunji Matsuki, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v: Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract This study examined the safety, tolerability, and pharmacokinetics (PK) of napabucasin in healthy Asian and non‐Asian participants and investigated the potential for QT/QTc interval prolongation. This five‐part (A–E) study proceeded in
Externí odkaz: https://doaj.org/article/b804592a5ce74d749d7cb7315b7cacf7
Zobrazit plný text záznamu
3
Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D 2 Receptor Occupancy in Clinical Settings
Autor: Yoshiko Tomita, Takeshi Takagaki, Hiroyoshi Kakuyama, Hironori Nishibe, Daisuke Nemoto, Atsushi Kitamura
Publikováno v: The Journal of Clinical Pharmacology. 61:1069-1080
Blonanserin is an atypical antipsychotic drug with high affinity and selective antagonism for dopamine D2 and D3 and serotonin 5-HT2A receptors. Blonanserin transdermal patch is the first transdermal formulation developed for the treatment of schizop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb902bb473a6bc0ac4859d97dea44061
https://doi.org/10.1002/jcph.1835
Zobrazit plný text záznamu
4
Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT4 receptor partial agonist, in healthy elderly and young subjects
Autor: Naoyuki Sawada, Yosuke Nakada, Takeshi Takagaki, Yuta Shibue, Hiroyoshi Kakuyama, Tatsuto Hamatani, Masayo Hashimoto
Publikováno v: Drug Metabolism and Pharmacokinetics. 35:563-570
Minesapride is a novel 5-hydroxytryptamine 4 (5-HT4) receptor partial agonist that is expected to show efficacy in patients with irritable bowel syndrome with predominant constipation and functional constipation. An open-label study was conducted to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e68aac23ce39bee0b14042df8d10f6c1
https://doi.org/10.1016/j.dmpk.2020.09.005
Zobrazit plný text záznamu
5
Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
Autor: Takeshi Sakayori, Hironori Nishibe, WooChan Kim, Amane Tateno, Masahiro Yamamoto, Hiroyoshi Kakuyama, Yoshiro Okubo
Publikováno v: International Journal of Neuropsychopharmacology
Background Transdermal antipsychotic patch formulations offer potential benefits, including improved adherence. This study investigated the striatal dopamine D2 receptor occupancy with daily blonanserin transdermal patch application. Methods This ope
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c68db06e0c1c5ed4b2b61cf1cd0c669
https://doi.org/10.1093/ijnp/pyaa071
Zobrazit plný text záznamu
6
A 3‐Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP‐6952 in Healthy Japanese Subjects and Those With ≤3 Spontaneous Bowel Movements per Week
Autor: Yuji Kumagai, Takuya Yumizaki, Mika Maeda, Tomoe Fujita, Hiroyoshi Kakuyama
Publikováno v: Clinical Pharmacology in Drug Development. 9:353-365
We hypothesized that DSP-6952, a partial agonist of the 5-hydroxytryptamine type-4 receptor and a gastrointestinal prokinetic agent, can induce natural bowel movements by enhancing gastrointestinal motility and colonic transit in patients with chroni
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::833755d92a0ee17ebdec9ae55afc6af4
https://doi.org/10.1002/cpdd.731
Zobrazit plný text záznamu
7
Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI-589 in Healthy Participants
Autor: Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v: Clinical pharmacology in drug developmentReferences. 11(10)
EPI-589 attenuates oxidative stress due to the radical scavenging activity of the reduced form and affects mitochondrial energy metabolism as a substrate of quinone-oxidoreductases. Given the effects of EPI-589 on oxidative stress and mitochondrial d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f73994aa72926a7600e5cd1ba49d77
https://pubmed.ncbi.nlm.nih.gov/35988057
Zobrazit plný text záznamu
10
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment
Autor: Takeshi Takagaki, Minoru Itou, Naoki Uchida, Kazuaki Inoue, Daisuke Ishii, Tomoe Fujita, Hiroyoshi Kakuyama
Publikováno v: Journal of clinical pharmacologyReferences. 60(10)
Ranirestat is an aldose reductase inhibitor hypothesized to improve diabetic neuropathy. An open-label, single-dose, parallel-group study was conducted to compare pharmacokinetic (PK) characteristics of an oral dose of ranirestat across subjects with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f78f790f41b0b7de90940330746200
https://pubmed.ncbi.nlm.nih.gov/32437025
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje